SNV1521 in Participants With Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
400 participants
Feb 23, 2024
INTERVENTIONAL
Conditions
Summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.
Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.
Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06220864